未登录 Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab Alban, Tyler J.; Riaz, Nadeem; Parthasarathy, Prerana; Makarov, Vladimir; Kendall, Sviatoslav; Yoo, Seong-Keun; Shah, Rachna; Weinhold, Nils; Srivastava, Raghvendra; Ma, Xiaoxiao; Krishna, Chirag; Mok, Juk Yee; van Esch, Wim J. E.; Garon, Edward; Akerley, Wallace; Creelan, Benjamin; Aanur, Nivedita; Chowell, Diego; Geese, William J.; Rizvi, Naiyer A.; Chan, Timothy A. 分享 收藏
Initial results from a phase 1a/1b study of STK-012, a first-in-class α/β IL-2 receptor biased partial agonist in advanced solid tumors (NCT05098132) Izar, Benjamin; Zamarin, Dmitriy; Spigel, David R.; Hoimes, Christopher J.; McDermott, David F.; Sehgal, Kartik; Najjar, Yana G.; Schoenfeld, Adam J.; Garon, Edward B.; Sullivan, Ryan J.; Henick, Brian S.; Leal, Ticiana A.; Hurwitz, Michael E.; McKay, Rana R.; Busby, Natalie; Mehta-Damani, Anita; Azrilevich, Alex; Tran, Tony; Rizvi, Naiyer; Oft, Martin; Spira, Alexander I. 分享 收藏
A Phase 1 study to evaluate the safety and tolerability of a combination autologous CD19 CAR T cell therapy (SYNCAR-001) and orthogonal IL-2 (STK-009) in subjects with relapsed or refractoryffx CD19 expressing hematologic malignancies (NCT05665062) Palomba, Maria Lia; Mei, Matthew G.; Caimi, Paolo F.; Cortese, Matthew; Davila, Marco; Yadnik, Greg; Huang, Nestor; Mou, David; Oft, Martin; Aspuria, Paul-Joseph; Mehta-Damani, Anita; Ratti, Navneet; Rizvi, Naiyer; Azrilevich, Alex; Reshef, Ran 分享 收藏
3-year update of neoadjuvant atezolizumab plus chemotherapy in patients with resectable non-small cell lung cancer Henick, Brian S.; Gainor, Justin F.; Awad, Mark M.; Chiuzan, Codruta; Izard, Stephanie; Georgis, Yohanna; Koch, Peter D.; Garofano, Robert F.; Wong, Cheryl V.; Saqi, Anjali; Grindheim, Jessica M.; Schulze, Katja; Rizvi, Naiyer A.; Izar, Benjamin; Taylor, Alison M.; Shu, Catherine A. 分享 收藏
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer Ravi, Arvind; Hellmann, Matthew D.; Arniella, Monica B.; Holton, Mark; Freeman, Samuel S.; Naranbhai, Vivek; Stewart, Chip; Leshchiner, Ignaty; Kim, Jaegil; Akiyama, Yo; Griffin, Aaron T.; Vokes, Natalie I.; Sakhi, Mustafa; Kamesan, Vashine; Rizvi, Hira; Ricciuti, Biagio; Forde, Patrick M.; Anagnostou, Valsamo; Riess, Jonathan W.; Gibbons, Don L.; Pennell, Nathan A.; Velcheti, Vamsidhar; Digumarthy, Subba R.; Mino-Kenudson, Mari; Califano, Andrea; Heymach, John V.; Herbst, Roy S.; Brahmer, Julie R.; Schalper, Kurt A.; Velculescu, Victor E.; Henick, Brian S.; Rizvi, Naiyer; Jaenne, Pasi A.; Awad, Mark M.; Chow, Andrew; Greenbaum, Benjamin D.; Luksza, Marta; Shaw, Alice T.; Wolchok, Jedd; Hacohen, Nir; Getz, Gad; Gainor, Justin F. 分享 收藏
Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab Alban, Tyler Joseph; Riaz, Nadeem; Parthasarathy, Prerana; Makarov, Vlad; Kendall, Slav; Yoo, Seong-Keun; Shah, Rachna; Weinhold, Nils; Srivastava, Raghvendra; Ma, Xiaoxiao; Krishna, Chirag; Garon, Edward; Akerley, Wallace; Creelan, Ben; Aanuren, Nivedita; Chowell, Diego; Geese, William; Rizvi, Naiyer; Chan, Timothy 分享 收藏
Immunoproteasome expression and checkpoint blockade response in advanced non-small cell lung cancer Naranbhai, Vivek; Ravi, Arvind; Hellmann, Matthew; Arniella, Monica; Holton, Mark; Freeman, Samuel; Stewart, Chip; Leshchiner, Ignaty; Kim, Jaegil; Akiyama, Yo; Griffin, Aaron; Vokes, Natalie; Sakhi, Mustafa; Kamesan, Vashine; Rizvi, Hira; Ricciuti, Biagio; Forde, Patrick; Anagnostou, Valsamo; Riess, Jonathan; Gibbons, Don; Pennell, Nathan; Velcheti, Vamsidhar; Digumarthy, Subba; Mino-Kenudson, Mari; Califano, Andrea; Heymach, John; Herbst, Roy; Brahmer, Julie; Schalper, Kurt; Velculescu, Victor; Henick, Brian; Rizvi, Naiyer; Janne, Pasi; Awad, Mark; Chow, Andrew; Greenbaum, Benjamin; Luksza, Marta; Shaw, Alice; Wolchok, Jedd; Hacohen, Nir; Getz, Gad; Gainor, Justin 分享 收藏
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy 癌症免疫治疗协会 (SITC) 对免疫检查点抑制剂联合化疗耐药的共识定义 Rizvi, Naiyer; Ademuyiwa, Foluso O.; Cao, Z. Alexander; Chen, Helen X.; Ferris, Robert L.; Goldberg, Sarah B.; Hellmann, Matthew D.; Mehra, Ranee; Rhee, Ina; Park, Jong Chul; Kluger, Harriet; Tawbi, Hussein; Sullivan, Ryan J. 分享 收藏
Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors Bukhari, Shoiab; Henick, Brian S.; Winchester, Robert J.; Lerrer, Shalom; Adam, Kieran; Gartshteyn, Yevgeniya; Maniar, Rohan; Lin, Ziyan; Khodadadi-Jamayran, Alireza; Tsirigos, Aristotelis; Salvatore, Mary M.; Lagos, Galina G.; Reiner, Steven L.; Dallos, Matthew C.; Mathew, Matthen; Rizvi, NaiyerA.; Mor, Adam 分享 收藏
Assessing Pathologic Response in Resected Lung Cancers: Current Standards, Proposal for a Novel Pathologic Response Calculator Tool, and Challenges in Practice Saqi, Anjali; Leslie, Kevin O.; Moreira, Andre L.; Lantuejoul, Sylvie; Shu, Catherine Ann; Rizvi, Naiyer A.; Sonett, Joshua R.; Tajima, Kosei; Sun, Shawn W.; Gitlitz, Barbara J.; V. Colby, Thomas 分享 收藏
Early circulating tumour DNA (ctDNA) dynamics for predicting and monitoring response to immunotherapy (IO) vs chemotherapy (CT) in patients with 1L metastatic (m) NSCLC: Analyses from the phase III MYSTIC trial Peters, S.; Rizvi, N. A.; Kuziora, M.; Lai, Z.; Shrestha, Y.; Dey, A.; Barrett, J. C.; Scheuring, U.; Poole, L.; Abbosh, C.; Raja, R.; Hellmann, M. D. 分享 收藏
Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC) Garon, Edward B.; Cho, Byoung Chul; Reinmuth, Niels; Lee, Ki Hyeong; Luft, Alexander; Ahn, Myung-Ju; Robinet, Gilles; Le Moulec, Sylvestre; Natale, Ronald; Schneider, Jeffrey; Shepherd, Frances A.; Garassino, Marina Chiara; Geater, Sarayut Lucien; Szekely, Zsolt Papai; Van Ngoc, Tran; Liu, Feng; Scheuring, Urban; Patel, Nikunj; Peters, Solange; Rizvi, Naiyer A. 分享 收藏
CD73 inhibitor oleclumab plus osimertinib for advanced EGFRm NSCLC: First report of a Phase 1b/2 study. Kim, Dong-Wan; Kim, Sang-We; Camidge, D. Ross; Rizvi, Naiyer A.; Marrone, Kristen A.; Le, Xiuning; Blakely, Collin; Park, Keunchil; Chang, Gee-Chen; Patel, Sandip Pravin; Cooper, Zachary A.; Kumar, Rakesh; Samadani, Ramin; McCombs, Rebecca; Pluta, Michael; Wu, Kevin Yufeng; Ramalingam, Suresh 分享 收藏
Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inibitor Response 体细胞HLA I类丢失是免疫逃避的一种广泛机制，它完善了肿瘤突变负荷作为检查点免疫反应生物标志物的用途 Montesion, Meagan; Murugesan, Karthikeyan; Jin, Dexter X.; Sharaf, Radwa; Sanchez, Nora; Guria, Ameet; Minker, Max; Li, Gerald; Fisher, Virginia; Sokol, Ethan S.; Pavlick, Dean C.; Moore, Jay A.; Braly, Alan; Singal, Gaurav; Fabrizio, David; Comment, Leah A.; Rizvi, Naiyer A.; Alexander, Brian M.; Frampton, Garrett M.; Hegde, Priti S.; Albacker, Lee A. 分享 收藏
Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC Ricciuti, Biagio; Naqash, Abdul Rafeh; Naidoo, Jarushka; Sehgal, Kartik; Miller, Adam; Kehl, Kenneth; Venkatraman, Deepti; Sands, Jacob; Lamberti, Giuseppe; Recondo, Gonzalo; Zhang, Jiajia; Macherla, Shravanti; Baig, Sameer; Walker, Paul; Rangachari, Deepa; Gainor, Justin F.; Costa, Daniel B.; Rizvi, Naiyer; Sholl, Lynette M.; Nishino, Mizuki; Henick, Brian; Farago, Anna F.; Awad, Mark M. 分享 收藏
EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% EMPOWER-Lung 1: III期一线 (1L) cemiplimab单药治疗与铂类双重化疗 (chemo) 治疗程序性细胞死亡的晚期非小细胞肺癌 (NSCLC)-配体1 (PD-L1) ≥ 50% Sezer, A.; Kilickap, S.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; Turk, H. M.; Cicin, I.; Bentsion, D.; Gladkov, O.; Clingan, P.; Sriuranpong, V.; Rizvi, N.; Li, S.; Lee, S.; Gullo, G.; Lowy, I.; Rietschel, P. 分享 收藏
Integrative genomic analysis of checkpoint blockade in lung cancer: A multi-institution SU2C collaborative Arniella, Monica; Ravi, Arvind; Stewart, Chip; Freeman, Sam; Awad, Mark; Forde, Patrick; Anagnostou, Valsamo; Henick, Brian; Riess, Jonathan; Gibbons, Don; Pennell, Nathan; Velcheti, Vamsidhar; Leshchiner, Ignaty; Kim, Jaegil; Digumarthy, Subba; Mino-Kenudson, Mari; Heymach, John; Hacohen, Nir; Rizvi, Naiyer; Herbst, Roy; Velculescu, Victor; Brahmer, Julie; Schalper, Kurt; Janne, Pasi; Wolchok, Jedd; Shaw, Alice; Gainor, Justin; Hellmann, Matthew; Getz, Gad 分享 收藏
Alignment of TMB measured on clinical samples: Phase IIB of the Friends of Cancer Research TMB Harmonization Project Merino, Diana M.; Yee, Laura M.; McShane, Lisa M.; Williams, P. Mickey; Vilimas, Tomas; Patidar, Rajesh; Barrett, J. Carl; Chen, Shu-Jen; Cheng, Jen-Hao; Conroy, Jeffrey M.; Cyanam, Dinesh; Eyring, Kenneth R.; Fabrizio, David A.; Funari, Vincent; Garcia, Elizabeth P.; Glenn, Sean T.; Gocke, Christopher D.; Gupta, Vikas; Haley, Lisa M.; Hellmann, Matthew D.; Keefer, Laurel; Keeler, Lauryn R.; Kennedy, Brett; Lazar, Alexander J.; MacConaill, Laura E.; Meier, Kristen L.; Papin, Arnaud; Rizvi, Naiyer A.; Sokol, Ethan; Stafford, Phillip; Thompson, John F.; Tom, Warren; Weigman, Victor J.; Xie, Mingchao; Zhao, Chen; Stewart, Mark D.; Allen, Jeff 分享 收藏
分享 收藏
Challenges in lung cancer therapy during the COVID-19 pandemic Calabro, Luana; Peters, Solange; Soria, Jean-Charles; Di Giacomo, Anna Maria; Barlesi, Fabrice; Covre, Alessia; Altomonte, Maresa; Vegni, Virginia; Gridelli, Cesare; Reck, Martin; Rizvi, Naiyer; Maio, Michele 分享 收藏
.png){kind=icon}
.png){kind=icon}
.png)
ANNALS OF ONCOLOGY.png)
OAAI
.png){kind=icon}
分享.png){kind=icon}
收藏